Imagine the year of 1934. Prohibition has just been ratified. Wouldn’t it have been great to have owned stocks from Anheuser-Busch back then, which over the next few decades became the largest brewer in the U.S. The opportunity to own the next Anheuser-Busch or Coors of the future is here, in the fast emerging industry that is the marijuana industry.
In the past, the thought of owning marijuana stocks was a fool’s dream. Today, it is a reality. Just like with alcohol stocks after the Prohibition ended, marijuana stocks now have their watershed moment. Legalized marijuana is still new, however the industry has taken off. Even though the marijuana industry tends to experience bouts of instability, there still marijuana stocks that are well worth investing in.
The best marijuana stocks to own right now are:
GW Pharmaceuticals:(GWPH) This biotech company is headquartered in the United Kingdom and has gained a lot of attention for its marijuana based antiepileptic drug Epidiolex. As of now, the drug has experienced success with patients reporting 39% less seizures than before, which confirms the effectiveness of cannabinoids. The FDA has also given GW Pharmaceuticals a seven-year exclusive right to use Epidiolex for treatment of tuberous sclerosis complex, which is a rare disorder known to cause many cases of epilepsy. This is called ‘orphan status,” or a right given certain drugs to treat rare diseases. Another of its cannabis-based drugs, Sativex, was approved for use in the treatment of cancer and multiple sclerosis in New Zealand and in Europe. With a lot of cash on hand and virtually zero debt, GW is ready to increase investments in more research and development, which means experts predict a rise in this marijuana stock’s market value.
AbbVie, Inc. (ABBV): This leading marijuana stock has marketed a marijuana-based drug called Marino. AbbVie, Inc. is a pharmaceutical firm that has reported rising revenues four years in a row. Additionally, its operating income has climbed continuously. Marinol, which has gained FDA approval, helps team stem nausea and vomiting in chemotherapy patients, as well as stimulate hunger in those with AIDS> However, Marinol is not considered remarkable in terms of the earnings that it is bringing in. It is not one of its top-selling drugs.
Unlike a majority of pharmaceutical companies, AbbVie concentrated solely on the U.S market. This can be risky since this marijuana stock’s price depends solely on its products domestic values.
Insys Therapeutics, Inc (INSY)
Despite its average track record over the previous three years and a big drop in operating income towards the start of 2017, INSYS Therapeutics has been developing a new synthetic cannabis drug to treat juvenile epilepsy. It has also launched another marijuana-based product called Syndros to help with chemotherapy-induced nausea and AIDS-related weight loss.
Although it markets many non-marijuana drugs, INSYS has been in a financial slump for three years now and its operating income made a sharp decline at the end of 2016. The company has had its share of legal problems including an Arizona state attorney who sued the company for fraud in connection with a marketing campaign it launched for Subsys, a painkilling opioid. This marijuana stock has experienced a lot of volatility, common for a biotech stock. Problems aside experts believe this marijuana stock will outpace the marijuana industry’s anticipated growth of 26% and 28% annual earnings growth over the next five years.
The Scotts Miracle-Gro Company (SMG)
The marijuana stock is based out of Marysville, Ohio and specializes in lawn and garden products. It has now entered the pesticide business and is developing a line of pesticides for marijuana plants. It will also be coming out with a string of products for people growing their own hemp. The company has spent million acquiring other marijuana companies, whereas the marijuana market has traditionally exercised caution when marketing to the general public, Black Magic has found its way into 165 Home Depot stores.
Aurora Cannabis (ACB)
Aurora Cannabis has been one of the most successful marijuana stocks of 2017. The company recently launched a line of edible marijuana products, and is working hard to establish itself as a fixture in the European marijuana market. In fact, Aurora Cannabis acquired German medical marijuana market leader Pedanois GmbH this past March.
Aurora is also in the process of building a greenhouse in Calgary. This stock has extended to Australia, where it took a 20% stake in the country’s first and biggest marijuana company.